Mutaflor® is a remedy for the treatment of gut diseases. The bacterium Escherichia coli (E. coli) strain Nissle 1917 - the active substance of Mutaflor® - is a natural colonizer of the gut. On its release in the colon, it acts anti-inflammatory and against disease-causing micro-organisms. In addition, it enhances the defence powers of the Mutaflor® is a natural colonizer of the gut. E.coli strain Nissle 1917 is a normal, non-pathogenic and non-invasive inhabitant of the human gut. By means of special adhesive organelles (fimbriae) the strain is able to attach to the mucin layer of the gut wall. The strain is well mobile by possessing flagellae, an advantage when colonizing the 1. Introduction. The nonpathogenic Escherichia coli strain Nissle 1917 (EcN) is among the most studied probiotic bacteria [1,2].Over 100 years, EcN has been actively used as a pharmaceutical product (trade name: Mutaflor) for the treatment of intestinal disorders, such as inflammatory bowel disease, ulcerative colitis, and diarrhea [].EcN is a successful colonizer of the human gut, possessing E. coli Nissle 1917 (EcN; Ardeypharm GmbH, Herdecke, Germany), its K5 capsule mutants, EcN∆kfiB and EcN∆kfiC 46 and E. Coli K12 strain MG1655 (CGSC7740) 70 were used in this study. All strains The percent of species adversely affected by Nissle 1917 was 40% for Pseudomonas, 50% for E. coli, Enterococcus and Staphylococcus, 100% for Klebsiella and Enterobacter, and 0% for Citrobacter and Serratia. Conclusions: Nissle 1917, the active agent in Mutaflor, inhibited or out competed most bacterial isolates. These mechanisms could be used Effects of Escherichia coli Nissle 1917 on the Porcine Gut Microbiota, Intestinal Epithelium and Immune System in Early Life. The pre-weaning period offers a 'window of opportunity' to modulate the porcine gut microbiota and immune system through dietary interventions such as EcN supplementation, and EcN induced T cell proliferation and .

mutaflor e coli nissle 1917